GSK

News

UK, US approve GSK's twice-yearly asthma drug

GSK scores a first approval in the UK for new severe asthma and CRSwNP therapy Exdensur, but a second in the US covers the asthma indication only.

News

GSK closes on approval of asthma hope depemokimab

GSK is poised for the first major approval of depemokimab, a long-acting drug for severe asthma that can be dosed just twice a year.

News

CHMP decision levels the playing field for GSK's RSV jab

GSK's RSV vaccine is poised for EU approval in all adults aged 18 and over, bringing it into line with rival shots from Pfizer and Moderna.

News

Gloved hand punches a karate pad held up

GSK unit and AnaptysBio trade lawsuits over Jemperli

A spat between GSK/Tesaro and AnaptysBio over cancer drug Jemperli has escalated into litigation, with both parties claiming breach of contract.

News

GSK pumps £45m into antimicrobial resistance projects

GSK has revealed the six projects it will fund with the Fleming Initiative on antimicrobial resistance, set up with Imperial College London last year.

News

Medical group advises against leucovorin for autism

The American Academy of Paediatrics has warned against leucovorin as a treatment for autism, citing a lack of evidence on safety and efficacy.

UK, US approve GSK's twice-yearly asthma drug

GSK closes on approval of asthma hope depemokimab

CHMP decision levels the playing field for GSK's RSV jab

GSK unit and AnaptysBio trade lawsuits over Jemperli

GSK pumps £45m into antimicrobial resistance projects

Medical group advises against leucovorin for autism

Ambros' $125m for pain disorder drug, and other financings

How to meet your physicians where they are online

GSK

Editor's Picks